CNS Pharmaceuticals, Inc
Price
FilingsNewest: 8-K, Director or officer changeOct 2 →Insiders1 insider bought $34,009 in 1 open-market buy. No sales.→HoldersIkarian Capital 9.3%Adar1 4.8%Stonepine 2.8%→Financing →PeersClosest companies: MBRX, RNAZ, SNTI→
From the filings
Figures
- Net income
- −$864,706last 12 months
- Operating cash flow
- −$15.2Mlast 12 months
- Cash and equivalents
- $20.0Mat the last balance sheet
- Shares outstanding
- 1.5M shareson issue